Literature DB >> 16209641

Liver tumors in wild flatfish: a histopathological, proteomic, and metabolomic study.

G D Stentiford1, M R Viant, D G Ward, P J Johnson, A Martin, Wei Wenbin, H J Cooper, B P Lyons, S W Feist.   

Abstract

Fish play host to viral, bacterial, and parasitic diseases in addition to non-infectious conditions such as cancer. The National Marine Monitoring Programme (NMMP) provides information to the U.K. Government on the health status of marine fish stocks. An aspect of this work relates to the presence of tumors and other pathologies in the liver of the offshore sentinel flatfish species, dab (Limanda limanda). Using internationally agreed quality assurance criteria, tumors and pre-tumors are diagnosed using histopathology. The current study has expanded upon this work by integrating these traditional diagnostic approaches with ones utilizing modern technologies for analysis of proteomic and metabolomic profiles of selected lesions. We have applied SELDI and FT-ICR technologies (for proteomic and metabolomic analyses, respectively) to tumor and non-tumor samples resected from the liver of dab. This combined approach has demonstrated how these technologies are able to identify protein and metabolite profiles that are specific to liver tumors. Using histopathology to classify "analysis groups" is key to the success of such an approach since it allows for elimination of spurious samples (e.g., those containing parasite infections) that may confuse interpretation of "omic" data. As such, the pathology laboratory plays a central role in collating information relating to particular specimens and in establishing sampling groups relative to specific diagnostic questions. In this study, we present pilot data, which illustrates that proteomics and metabolomics can be used to discriminate fish liver tumors and suggest future directions for work of this type.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16209641     DOI: 10.1089/omi.2005.9.281

Source DB:  PubMed          Journal:  OMICS        ISSN: 1536-2310


  7 in total

1.  Toxicogenomics in regulatory ecotoxicology.

Authors:  Gerald T Ankley; George P Daston; Sigmund J Degitz; Nancy D Denslow; Robert A Hoke; Sean W Kennedy; Ann L Miracle; Edward J Perkins; Jason Snape; Donald E Tillitt; Charles R Tyler; Donald Versteeg
Journal:  Environ Sci Technol       Date:  2006-07-01       Impact factor: 9.028

2.  A signal filtering method for improved quantification and noise discrimination in fourier transform ion cyclotron resonance mass spectrometry-based metabolomics data.

Authors:  Tristan G Payne; Andrew D Southam; Theodoros N Arvanitis; Mark R Viant
Journal:  J Am Soc Mass Spectrom       Date:  2009-02-07       Impact factor: 3.109

Review 3.  Metabolomics in the study of spontaneous animal diseases.

Authors:  Helena Tran; Malcolm McConville; Panayiotis Loukopoulos
Journal:  J Vet Diagn Invest       Date:  2020-08-18       Impact factor: 1.279

4.  Metabolomics-based approach for assessing the toxicity mechanisms of dibutyl phthalate to abalone (Haliotis diversicolor supertexta).

Authors:  Jin Zhou; Baiyang Chen; Zhonghua Cai
Journal:  Environ Sci Pollut Res Int       Date:  2014-11-22       Impact factor: 4.223

5.  Biomarker discovery in animal health and disease: the application of post-genomic technologies.

Authors:  Rowan E Moore; Jennifer Kirwan; Mary K Doherty; Phillip D Whitfield
Journal:  Biomark Insights       Date:  2007-07-10

Review 6.  The metabolomic window into hepatobiliary disease.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  J Hepatol       Date:  2013-05-25       Impact factor: 25.083

Review 7.  Finfish and aquatic invertebrate pathology resources for now and the future.

Authors:  Jan M Spitsbergen; Vicki S Blazer; Paul R Bowser; Keith C Cheng; Keith R Cooper; Timothy K Cooper; Salvatore Frasca; David B Groman; Claudia M Harper; Jerry M Mac Law; Gary D Marty; Roxanna M Smolowitz; Judy St Leger; Douglas C Wolf; Jeffrey C Wolf
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2008-10-09       Impact factor: 3.228

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.